Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience
Objective: Our aim was to evaluate the safety of COVID-19 vaccine in children resident in the Latina Local Health Authority. Methods: We conducted a telephone survey among children aged 5–11 years receiving BNT162b2 mRNA COVID-19 vaccine between December 15 and 21. The main outcomes included the pre...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/8/1224 |
| _version_ | 1827598054353534976 |
|---|---|
| author | Silvia Bloise Alessia Marcellino Beatrice Frasacco Pietro Gizzone Claudia Proietti Ciolli Vanessa Martucci Mariateresa Sanseviero Emanuela Del Giudice Flavia Ventriglia Riccardo Lubrano |
| author_facet | Silvia Bloise Alessia Marcellino Beatrice Frasacco Pietro Gizzone Claudia Proietti Ciolli Vanessa Martucci Mariateresa Sanseviero Emanuela Del Giudice Flavia Ventriglia Riccardo Lubrano |
| author_sort | Silvia Bloise |
| collection | DOAJ |
| description | Objective: Our aim was to evaluate the safety of COVID-19 vaccine in children resident in the Latina Local Health Authority. Methods: We conducted a telephone survey among children aged 5–11 years receiving BNT162b2 mRNA COVID-19 vaccine between December 15 and 21. The main outcomes included the presence of allergic reactions or anaphylaxis, adverse events after 24–48 h, 7 and 20 days of taking the first and second doses of medications, and documented SARS-CoV-2 infection after vaccination. The information obtained was automatically linked to a spreadsheet and analyzed. Results: 569 children were enrolled. The mean age was 114 ± 4.24 months; there were 251 males in the study. The vaccine showed a favorable safety profile; no anaphylaxis or serious adverse events were reported. The most common symptoms both after the first and second dose were injection site reactions, asthenia, and headache. Injection site reactions were more frequent after the first dose (<i>p</i> = 0.01), while systemic symptoms were more frequent after the second dose (<i>p</i> = 0.022). These symptoms were more frequent in patients with comorbidities (<i>p</i> = 0.0159). Conclusion: Our findings confirm the safety of COVID-19 vaccine in children younger 11 years and could be useful to promote its diffusion in pediatric ages in order to achieve “herd immunity” and prevent the virus’s circulation. |
| first_indexed | 2024-03-09T03:43:04Z |
| format | Article |
| id | doaj.art-0fb237e6e42146e7a25875b2585465a5 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T03:43:04Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-0fb237e6e42146e7a25875b2585465a52023-12-03T14:36:46ZengMDPI AGVaccines2076-393X2022-07-01108122410.3390/vaccines10081224Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric ExperienceSilvia Bloise0Alessia Marcellino1Beatrice Frasacco2Pietro Gizzone3Claudia Proietti Ciolli4Vanessa Martucci5Mariateresa Sanseviero6Emanuela Del Giudice7Flavia Ventriglia8Riccardo Lubrano9Dipartimento Materno Infantile e di Scienze Urologiche, Sapienza Università di Roma, UOC di Pediatria e Neonatologia-Polo Pontino, 04100 Latina, ItalyDipartimento Materno Infantile e di Scienze Urologiche, Sapienza Università di Roma, UOC di Pediatria e Neonatologia-Polo Pontino, 04100 Latina, ItalyDipartimento Materno Infantile e di Scienze Urologiche, Sapienza Università di Roma, UOC di Pediatria e Neonatologia-Polo Pontino, 04100 Latina, ItalyDipartimento Materno Infantile e di Scienze Urologiche, Sapienza Università di Roma, UOC di Pediatria e Neonatologia-Polo Pontino, 04100 Latina, ItalyDipartimento Materno Infantile e di Scienze Urologiche, Sapienza Università di Roma, UOC di Pediatria e Neonatologia-Polo Pontino, 04100 Latina, ItalyDipartimento Materno Infantile e di Scienze Urologiche, Sapienza Università di Roma, UOC di Pediatria e Neonatologia-Polo Pontino, 04100 Latina, ItalyDipartimento Materno Infantile e di Scienze Urologiche, Sapienza Università di Roma, UOC di Pediatria e Neonatologia-Polo Pontino, 04100 Latina, ItalyDipartimento Materno Infantile e di Scienze Urologiche, Sapienza Università di Roma, UOC di Pediatria e Neonatologia-Polo Pontino, 04100 Latina, ItalyDipartimento Materno Infantile e di Scienze Urologiche, Sapienza Università di Roma, UOC di Pediatria e Neonatologia-Polo Pontino, 04100 Latina, ItalyDipartimento Materno Infantile e di Scienze Urologiche, Sapienza Università di Roma, UOC di Pediatria e Neonatologia-Polo Pontino, 04100 Latina, ItalyObjective: Our aim was to evaluate the safety of COVID-19 vaccine in children resident in the Latina Local Health Authority. Methods: We conducted a telephone survey among children aged 5–11 years receiving BNT162b2 mRNA COVID-19 vaccine between December 15 and 21. The main outcomes included the presence of allergic reactions or anaphylaxis, adverse events after 24–48 h, 7 and 20 days of taking the first and second doses of medications, and documented SARS-CoV-2 infection after vaccination. The information obtained was automatically linked to a spreadsheet and analyzed. Results: 569 children were enrolled. The mean age was 114 ± 4.24 months; there were 251 males in the study. The vaccine showed a favorable safety profile; no anaphylaxis or serious adverse events were reported. The most common symptoms both after the first and second dose were injection site reactions, asthenia, and headache. Injection site reactions were more frequent after the first dose (<i>p</i> = 0.01), while systemic symptoms were more frequent after the second dose (<i>p</i> = 0.022). These symptoms were more frequent in patients with comorbidities (<i>p</i> = 0.0159). Conclusion: Our findings confirm the safety of COVID-19 vaccine in children younger 11 years and could be useful to promote its diffusion in pediatric ages in order to achieve “herd immunity” and prevent the virus’s circulation.https://www.mdpi.com/2076-393X/10/8/1224COVID-19vaccinechildrenadverse events |
| spellingShingle | Silvia Bloise Alessia Marcellino Beatrice Frasacco Pietro Gizzone Claudia Proietti Ciolli Vanessa Martucci Mariateresa Sanseviero Emanuela Del Giudice Flavia Ventriglia Riccardo Lubrano Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience Vaccines COVID-19 vaccine children adverse events |
| title | Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience |
| title_full | Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience |
| title_fullStr | Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience |
| title_full_unstemmed | Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience |
| title_short | Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience |
| title_sort | cross sectional survey on bnt162b2 mrna covid 19 vaccine serious adverse events in children 5 to 11 years of age a monocentric experience |
| topic | COVID-19 vaccine children adverse events |
| url | https://www.mdpi.com/2076-393X/10/8/1224 |
| work_keys_str_mv | AT silviabloise crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience AT alessiamarcellino crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience AT beatricefrasacco crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience AT pietrogizzone crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience AT claudiaproietticiolli crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience AT vanessamartucci crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience AT mariateresasanseviero crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience AT emanueladelgiudice crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience AT flaviaventriglia crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience AT riccardolubrano crosssectionalsurveyonbnt162b2mrnacovid19vaccineseriousadverseeventsinchildren5to11yearsofageamonocentricexperience |